Companies ›Healthcare ›INNO.CD

INNO.CD — — Pharmaceuticals

Inno.Cd

$5,00

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

-4,7 %

ROE

-20,1 %

Net margin

-4,2 %

Debt / equity

0,17

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

INNO.CD is a pharmaceutical company that develops and commercializes innovative therapies, primarily in the field of oncology and rare diseases.

Business. INNO.CD is a pharmaceutical company that develops and commercializes innovative therapies, primarily in the field of oncology and rare diseases.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

-20,1 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning INNO.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to INNO.CD. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

INNO.CD is a pharmaceutical company that develops and commercializes innovative therapies, primarily in the field of oncology and rare diseases.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

AI synthesis

GENERATED

INNO.CD has a current liquidity position characterized by a current ratio of 7.7, indicating strong short-term liquidity. However, the company reported negative net cash after subtracting total debt, which raises concerns about its ability to meet short-term obligations without external financing. The company's debt-to-equity ratio of 0.17 suggests a relatively conservative capital structure, with limited leverage.

Profitability metrics for INNO.CD are weak, with a return on equity of -20.08% and a return on assets of -10.68%. These figures indicate that the company is not generating returns that exceed its cost of capital, which is a significant concern in the pharmaceutical industry where high R&D costs and long development cycles are the norm. The company's operating income was -$1.26 million, and net income was -$1.12 million, reflecting ongoing losses.

INNO.CD's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financial data. This lack of diversification increases the company's exposure to market-specific risks, particularly in the pharmaceutical sector where regulatory and reimbursement environments can vary significantly by region.

Looking ahead, the company's revenue outlook is uncertain, with no clear guidance provided in the latest financial statements. The company's free cash flow was -$315,000, and capital expenditures were -$16,000, indicating limited reinvestment in the business. These figures suggest that the company may need to rely on external financing to fund its operations and growth initiatives.

The risk assessment for INNO.CD highlights medium liquidity risk and low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating potential liquidity constraints. The company has not disclosed any significant dilution sources in the latest filings, and the dilution risk is currently assessed as low.

Recent events for INNO.CD include the continued development of its pipeline in oncology and rare diseases, with no major regulatory approvals or product launches disclosed in the latest financial data. The company's ongoing losses and negative cash flow suggest that it is in the early stages of commercialization or facing challenges in bringing its products to market.

Key takeaways

INNO.CD has a strong current ratio of 7.7 but faces liquidity concerns due to negative net cash after subtracting total debt.
The company is unprofitable, with a return on equity of -20.08% and a return on assets of -10.68%.
Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
The company's free cash flow is negative, and capital expenditures are minimal, indicating limited reinvestment in the business.
The risk assessment highlights medium liquidity risk and low dilution risk.

Bull / Bear case

analysis pipeline

— missing data

In focus — financials by report

Valuation

Market price

$5,00

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$5.6M

Net cashⓘ

-$930.0k

Current ratioⓘ

7.7

Debt / equityⓘ

0.2

ROAⓘ

-10.7%

ROEⓘ

-20.1%

Cash conversionⓘ

-44.0%

CapEx / revenueⓘ

-0.1%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin-4,7 %Below median

Net Margin-4,2 %Below median

ROE-20,1 %Bottom quartile

Capex / Rev-0,1 %Above P75

D/E0,17Below median

Cash Conv-0,44Bottom quartile

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

INNO.CD Market data — financials · 2026-05-28

Ownership & reference

Leadership

Ron MayronExecutive Chairman of the Board

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

INNO.CDCanonical

— · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread